Drug Profile
Research programme: anticancer therapies - Moleculin Biotech/University of Texas M D Anderson Cancer Center
Alternative Names: CP2005; Degrasyns; Tyrphostins; WP 1234; WP1106; WP1129; WP1130Latest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer Moleculin
- Class Antineoplastics; Small molecules
- Mechanism of Action Apoptosis stimulants; Bcr-abl tyrosine kinase inhibitors; Glycolysis inhibitors; Janus kinase-2 inhibitors; STAT3 transcription factor inhibitors; Ubiquitin protein ligase complex modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in USA (IV)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 15 Nov 2018 Moleculin Biotech announces intention to submit IND application to the US FDA